Correction: Relationship between sacral-abdominal wall distance, movement performance, and spinal alignment in osteoporosis: a retrospective study
(Source: BMC Geriatrics)
Source: BMC Geriatrics - May 2, 2024 Category: Geriatrics Authors: Takashi Nagai, Makoto Miyagami, Shota Nakamura, Keizo Sakamoto, Koji Ishikawa, Ichiro Okano, Fumihito Kasai, Yoshifumi Kudo and Nobuyuki Kawate Tags: Correction Source Type: research
Mortality, bone density and grip strength: lessons from the past and hope for the future?
CONCLUSION: We report strong relationships between grip strength and mortality compared with BMD. We hypothesize that this may reflect better recognition and treatment of low BMD in this cohort.PMID:38690291 | PMC:PMC11057971 | DOI:10.1093/rap/rkae046 (Source: Adv Data)
Source: Adv Data - May 1, 2024 Category: Epidemiology Authors: Leo D Westbury Faidra Laskou Harnish P Patel Cyrus Cooper Elaine M Dennison Source Type: research
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
CONCLUSION: Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers shou...
Source: Addiction Science and Clinical Practice - May 1, 2024 Category: Addiction Authors: Pankti P Acharya Crystal Joseph Source Type: research
Effects of Empagliflozin on vascular and skeletal mineralization in Hyperlipidemic mice
Vascul Pharmacol. 2024 Apr 29:107376. doi: 10.1016/j.vph.2024.107376. Online ahead of print.ABSTRACTCardiovascular disease and osteoporosis, major causes of morbidity and mortality, are associated with hyperlipidemia. Recent studies show that empagliflozin (EMPA), an inhibitor of sodium-glucose cotransporter-2 (SGLT2), improves cardiovascular health. In preclinical animal studies, EMPA mitigates vascular calcification in the males but its effects in the females are not known. Thus, we used female mice to test the effects of EMPA on calcification in the artery wall, cardiac function, and skeletal bone. By serial in vivo mic...
Source: Vascular Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sophia Kalanski Stuti Pradhan Andy Hon Yuxuan Xia Nora Safvati Juan Carlos Rivera Mimi Lu Linda L Demer Yin Tintut Source Type: research
Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
Eur J Pharmacol. 2024 Apr 29:176630. doi: 10.1016/j.ejphar.2024.176630. Online ahead of print.ABSTRACTOsteoporosis is the most common bone disorder, in which an imbalance between osteoclastic bone resorption and osteoblastic bone formation disrupts bone homeostasis. Osteoporosis management using anti-osteoclastic agents is a promising strategy; however, this remains an unmet need. Sphingosine-1-phosphate (S1P) and its receptors (S1PRs) are essential for maintaining bone homeostasis. Here, we identified that Siponimod, a Food and Drug Administration-approved S1PR antagonist for the treatment of multiple sclerosis, shows pro...
Source: European Journal of Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sitao Hu Yangyang Hu Zenglin Tan Chengyu Zhou Cheng Zhang Sheng Yin Xiaojun Chen Kai Chen Lu Wang Lei Chen Source Type: research
Development of Transdermal Formulation Based on Nanotechnology and Elucidation of Its Drug Delivery Pathways
Yakugaku Zasshi. 2024;144(5):505-510. doi: 10.1248/yakushi.23-00178-1.ABSTRACTTransdermal drug delivery is a formulation in which the drug is absorbed through the skin for systemic action. Its advantages include avoidance of first-pass effects, sustained drug supply, and ease of administration and discontinuation. Drugs administered transdermally transfer into the blood circulation through the stratum corneum, epidermis, and dermis. The stratum corneum on the skin surface plays a barrier function in skin absorption. Therefore, developing of transdermal drug delivery systems requires innovations that overcome the barrier fu...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - May 1, 2024 Category: Drugs & Pharmacology Authors: Hiroko Otake Noriaki Nagai Source Type: research
Mortality, bone density and grip strength: lessons from the past and hope for the future?
CONCLUSION: We report strong relationships between grip strength and mortality compared with BMD. We hypothesize that this may reflect better recognition and treatment of low BMD in this cohort.PMID:38690291 | PMC:PMC11057971 | DOI:10.1093/rap/rkae046 (Source: Adv Data)
Source: Adv Data - May 1, 2024 Category: Epidemiology Authors: Leo D Westbury Faidra Laskou Harnish P Patel Cyrus Cooper Elaine M Dennison Source Type: research
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
CONCLUSION: Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers shou...
Source: Addiction Science and Clinical Practice - May 1, 2024 Category: Addiction Authors: Pankti P Acharya Crystal Joseph Source Type: research
Effects of Empagliflozin on vascular and skeletal mineralization in Hyperlipidemic mice
Vascul Pharmacol. 2024 Apr 29:107376. doi: 10.1016/j.vph.2024.107376. Online ahead of print.ABSTRACTCardiovascular disease and osteoporosis, major causes of morbidity and mortality, are associated with hyperlipidemia. Recent studies show that empagliflozin (EMPA), an inhibitor of sodium-glucose cotransporter-2 (SGLT2), improves cardiovascular health. In preclinical animal studies, EMPA mitigates vascular calcification in the males but its effects in the females are not known. Thus, we used female mice to test the effects of EMPA on calcification in the artery wall, cardiac function, and skeletal bone. By serial in vivo mic...
Source: Vascular Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sophia Kalanski Stuti Pradhan Andy Hon Yuxuan Xia Nora Safvati Juan Carlos Rivera Mimi Lu Linda L Demer Yin Tintut Source Type: research
Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
Eur J Pharmacol. 2024 Apr 29:176630. doi: 10.1016/j.ejphar.2024.176630. Online ahead of print.ABSTRACTOsteoporosis is the most common bone disorder, in which an imbalance between osteoclastic bone resorption and osteoblastic bone formation disrupts bone homeostasis. Osteoporosis management using anti-osteoclastic agents is a promising strategy; however, this remains an unmet need. Sphingosine-1-phosphate (S1P) and its receptors (S1PRs) are essential for maintaining bone homeostasis. Here, we identified that Siponimod, a Food and Drug Administration-approved S1PR antagonist for the treatment of multiple sclerosis, shows pro...
Source: European Journal of Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sitao Hu Yangyang Hu Zenglin Tan Chengyu Zhou Cheng Zhang Sheng Yin Xiaojun Chen Kai Chen Lu Wang Lei Chen Source Type: research
Development of Transdermal Formulation Based on Nanotechnology and Elucidation of Its Drug Delivery Pathways
Yakugaku Zasshi. 2024;144(5):505-510. doi: 10.1248/yakushi.23-00178-1.ABSTRACTTransdermal drug delivery is a formulation in which the drug is absorbed through the skin for systemic action. Its advantages include avoidance of first-pass effects, sustained drug supply, and ease of administration and discontinuation. Drugs administered transdermally transfer into the blood circulation through the stratum corneum, epidermis, and dermis. The stratum corneum on the skin surface plays a barrier function in skin absorption. Therefore, developing of transdermal drug delivery systems requires innovations that overcome the barrier fu...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - May 1, 2024 Category: Drugs & Pharmacology Authors: Hiroko Otake Noriaki Nagai Source Type: research
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
CONCLUSION: Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers shou...
Source: Addiction Science and Clinical Practice - May 1, 2024 Category: Addiction Authors: Pankti P Acharya Crystal Joseph Source Type: research
Effects of Empagliflozin on vascular and skeletal mineralization in Hyperlipidemic mice
Vascul Pharmacol. 2024 Apr 29:107376. doi: 10.1016/j.vph.2024.107376. Online ahead of print.ABSTRACTCardiovascular disease and osteoporosis, major causes of morbidity and mortality, are associated with hyperlipidemia. Recent studies show that empagliflozin (EMPA), an inhibitor of sodium-glucose cotransporter-2 (SGLT2), improves cardiovascular health. In preclinical animal studies, EMPA mitigates vascular calcification in the males but its effects in the females are not known. Thus, we used female mice to test the effects of EMPA on calcification in the artery wall, cardiac function, and skeletal bone. By serial in vivo mic...
Source: Vascular Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sophia Kalanski Stuti Pradhan Andy Hon Yuxuan Xia Nora Safvati Juan Carlos Rivera Mimi Lu Linda L Demer Yin Tintut Source Type: research
Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
Eur J Pharmacol. 2024 Apr 29:176630. doi: 10.1016/j.ejphar.2024.176630. Online ahead of print.ABSTRACTOsteoporosis is the most common bone disorder, in which an imbalance between osteoclastic bone resorption and osteoblastic bone formation disrupts bone homeostasis. Osteoporosis management using anti-osteoclastic agents is a promising strategy; however, this remains an unmet need. Sphingosine-1-phosphate (S1P) and its receptors (S1PRs) are essential for maintaining bone homeostasis. Here, we identified that Siponimod, a Food and Drug Administration-approved S1PR antagonist for the treatment of multiple sclerosis, shows pro...
Source: European Journal of Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Authors: Sitao Hu Yangyang Hu Zenglin Tan Chengyu Zhou Cheng Zhang Sheng Yin Xiaojun Chen Kai Chen Lu Wang Lei Chen Source Type: research
Development of Transdermal Formulation Based on Nanotechnology and Elucidation of Its Drug Delivery Pathways
Yakugaku Zasshi. 2024;144(5):505-510. doi: 10.1248/yakushi.23-00178-1.ABSTRACTTransdermal drug delivery is a formulation in which the drug is absorbed through the skin for systemic action. Its advantages include avoidance of first-pass effects, sustained drug supply, and ease of administration and discontinuation. Drugs administered transdermally transfer into the blood circulation through the stratum corneum, epidermis, and dermis. The stratum corneum on the skin surface plays a barrier function in skin absorption. Therefore, developing of transdermal drug delivery systems requires innovations that overcome the barrier fu...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - May 1, 2024 Category: Drugs & Pharmacology Authors: Hiroko Otake Noriaki Nagai Source Type: research
